All Stories

  1. RWD-derived response in multiple myeloma

    Article • PLoS ONE, May 2023, PLOS

    Shaji K Kumar

  2. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis

    Article • Amyloid, September 2019, Taylor & Francis

    Eli Muchtar, Dr Nelson Leung, Shaji K Kumar

  3. Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

    Article • Leukemia & Lymphoma, May 2019, Taylor & Francis

    Dr Nelson Leung, Shaji K Kumar

  4. Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria

    Article • Amyloid, March 2019, Taylor & Francis

    Eli Muchtar, Shaji K Kumar

  5. Precision medicine in multiple myeloma: are we there yet?

    Article • Expert Review of Precision Medicine and Drug Development, February 2019, Taylor & Francis

    Shaji K Kumar

  6. Stem-cell transplantation in multiple myeloma: how far have we come?

    Article • Therapeutic Advances in Hematology, January 2019, SAGE Publications

    Shaji K Kumar

  7. Daratumumab in untreated newly diagnosed multiple myeloma

    Article • Therapeutic Advances in Hematology, January 2019, SAGE Publications

    Shaji K Kumar

  8. Ixazomib for the treatment of multiple myeloma

    Article • Expert Opinion on Pharmacotherapy, November 2018, Taylor & Francis

    Shaji K Kumar

  9. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?

    Article • Amyloid, March 2018, Taylor & Francis

    Eli Muchtar, Shaji K Kumar

  10. The evolution of stem-cell transplantation in multiple myeloma

    Article • Therapeutic Advances in Hematology, March 2018, SAGE Publications

    Shaji K Kumar

  11. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise

    Article • Leukemia & Lymphoma, January 2018, Taylor & Francis

    Shaji K Kumar

  12. New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib

    Article • Journal of Blood Medicine, August 2017, Dove Medical Press

    Shaji K Kumar

  13. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis

    Article • Amyloid, July 2017, Taylor & Francis

    Dr Nidhi Tandoj, Dr Nelson Leung, Shaji K Kumar

  14. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition

    Article • Annals of Medicine, March 2017, Taylor & Francis

    Shaji K Kumar, Dr Nelson Leung, Eli Muchtar

  15. Clinical use and applications of histone deacetylase inhibitors in multiple myeloma

    Article • Clinical Pharmacology Advances and Applications, May 2016, Dove Medical Press

    Dr Nidhi Tandoj, Shaji K Kumar

  16. Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases

    Article • Clinical Journal of the American Society of Nephrology, September 2012, American Society of Nephrology

    Shaji K Kumar, Dr Nelson Leung, Dr Fernando Fervenza, Sanjeev Sethi